Humanized Antibodies Neutralizing Hepatitis B Surface Antigen
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic drugs for hepatitis B, such as nucleoside analogues, face challenges with resistant virus emergence and the limitations of human plasma-derived hepatitis B antibody agents in meeting demand and cost, while mouse-derived monoclonal antibodies can induce human anti-mouse antibody reactions, limiting their therapeutic efficacy for chronic hepatitis treatment.
Innovation Solution
Development of novel antibodies specifically binding to hepatitis B virus surface antigen, comprising specific heavy and light chain variable regions, constant regions, and expression vectors, which are used to create a pharmaceutical composition for preventing or treating hepatitis B, utilizing a phage display method to select antibodies with high affinity and neutralizing ability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nucleoside analogues are used to treat hepatitis B, then HBV DNA polymerase is inhibited, but resistant viruses emerge leading to decreased therapeutic efficacy
Solution Approach 1:
The patent uses phage display technology to create copies of antibody genes that bind to HBV surface antigen, selecting and amplifying high-affinity binding variants. This copying approach allows identification of antibodies with sustained neutralizing activity that does not induce viral resistance like nucleoside analogues
Solution Approach 2:
The patent modifies antibody parameters through iterative phage display selection processes, optimizing binding affinity and neutralizing capacity. The selected antibodies demonstrate sustained therapeutic effect without the resistance development problem seen with nucleoside analogues
2Reliability
If human plasma-derived hepatitis B antibody agents are used, then therapeutic effect is achieved, but availability is limited and cost is high
Solution Approach 1:
The patent employs phage display technology where the system itself selects and optimizes antibody candidates against HBV surface antigen. This self-service approach eliminates dependence on limited human plasma sources while maintaining high therapeutic efficacy through computationally guided selection of high-affinity binders
Solution Approach 2:
The patent creates composite antibody molecules with optimized variable regions selected through phage display and human constant regions. This composite approach combines the high affinity of selected variable regions with the therapeutic properties of human antibodies, achieving both availability and efficacy
3Measurement precision
If mouse-derived monoclonal antibodies are used, then high affinity binding is achieved, but human anti-mouse antibody reactions occur limiting therapeutic use
Solution Approach 1:
The patent applies local quality by replacing only the variable regions of mouse antibodies with human variable regions selected through phage display. This localized humanization maintains the high binding affinity of the original mouse antibodies while eliminating the HAMA response by using human constant regions and human variable region sequences
Solution Approach 2:
The patent creates humanized copies of mouse monoclonal antibodies by selecting human variable region sequences through phage display that replicate the binding characteristics of mouse antibodies. These humanized copies maintain high affinity for HBV surface antigen while being immunologically compatible with human patients
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies effectively neutralize hepatitis B virus surface antigen, providing a promising solution for preventing or treating hepatitis B by reducing antigen levels in the blood, thus addressing the limitations of existing therapies.
Implementation Method 1
a methodology of preparing a monoclonal antibody (mAb) was established by Köhler and Milstein (1975), monoclonal antibodies derived from mice have been mainly used for diagnosis or some treatment
Implementation Method 2
The antibodies effectively neutralize hepatitis B virus surface antigen, providing a promising solution for preventing or treating hepatitis B by reducing antigen levels in the blood
Data Source
AI summary
Provided are antibodies specifically binding to the HBV surface antigen (HBsAg) which are effective for the prevention or treatment of hepatitis B.